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Editorial
What about HES in burn patients?$
Evaluation of the actual evidence
Following the 2013 alert by the European Medicines Agency
(EMA) discouraging the use of hydroxyethyl-starch solutions
(HES) in critically ill and burn patients [1], most specialized
units treating burn victims have stopped using HES in this
population. But, how well-founded was the EMA alert in this
specific type of patient?
A major burn patient is defined as one with burn injury
affecting at least 20% or 30% of the body surface area (BSA). At
this percentage, the patient experiences a systemic impact,
characterized by an inflammatory response with microvascu-
lar changes that lead to altered capillary permeability, and
hypovolemic and cell shock, commonly known as burn shock
[2]. It is recognized that intravenous fluid resuscitation is
essential to improve survival in major burn patients, as they
are in an exceptionally severe clinical state. In addition to the
above-mentioned systemic changes, they may experience
massive bleeding when undergoing surgical treatment for
their injuries and are highly susceptible to the development of
infection. But not all victims of burn injury are major burn
patients, and not all develop sepsis or have the same systemic
repercussions. The different etiologies and severity of the
lesions makes this a very heterogeneous patient population,
and it is surprising that the European Medicines Agency
considers them all in the same manner with respect to HES
administration.
We believe that the alert emitted, which explicitly says
“Hydroxyethyl-starches (HES) should no longer be used in
patients with sepsis, burn injuries or critically ill patients” [1]
lacks specific information. Given that there is considerable
variability in the characteristics of burn patients and that these
require advanced fluid therapy management [2], data are
needed on the severity of the injury, the affected BSA, systemic
involvement, and the time during which this recommendation
should be applied.
Several questions come to mind in relation to this
recommendation: Should solar burns or 1% burns be taken
into account in a trauma patient with bleeding? Is it only
appropriate for major burns? How long should it be applied?
During the first 24h, as is done with the remaining colloids in
patients with burns? One week? One month? And what is quite
important: on what basis did this specific recommendation for
burn patients emerge?
When the alert was communicated, it was based on a series
of large, recently published studies: 6S [3], CRYSTMAS [4],
CHEST [5], CRISTAL [6], and VISEP [7]. But, were burn patients
actually included in these studies? To answer our concerns
about the current recommendations for these patients, we set
out to review the methods used in these studies, and here we
present our results.
The 6S study [3], involving 798 patients and excluding
those with burns affecting >10% BSA, compared mortality
and acute kidney injury after initial resuscitation with
Ringer’s acetate (RA) versus HES 130/0.42. It is surprising
that only burns involving <10% BSA were accepted, when
these patients are not usually considered critically ill and are
unlikely to develop severe sepsis. The study concluded that
patients with severe sepsis or septic shock receiving HES had
a higher risk of death and renal replacement requirement at
90days than those given RA. Of note, patients were
randomized after the first 24h, once they had been stabilized
and when they may already have received 1liter of synthetic
colloids, as in the majority of these studies [3,5,8]. Further-
more, 38 patients in the RA group received synthetic colloids
without being excluded from the statistical analysis. As to
the results, there were no significant differences in mortality
at 28 days, but differences were seen at 90 days. Mortality
was related to the requirement for renal replacement
therapy (RRT), but the indications for this therapy were
not defined in the study protocol and were left to the
discretion of the attending physician. The number of
patients with a definite RRT requirement was exactly the
same in the two groups. There were no significant differ-
ences between the groups for the authors’ defined measure
of renal failure, for the urinary output (UO) values, or for
patients with doubling of plasma creatinine levels. With
regard to the RIFLE score, the raw data were given in an
appendix, but statistical significance was not calculated. No
significant differences were seen for the overall SOFA score,
but the renal subscore data were not provided; instead, they
were combined with those of patients undergoing RRT.
$ This manuscript was not screened for plagiarism.
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The multicenter CRYSTMAS [4] study, including 196 pa-
tients with severe sepsis, compared the volume of HES (130/
0.4) versus 0.9% saline needed to hemodynamically stabilize
patients, and concluded that a significantly lower volume of
HES was infused on the first day. There were no significant
differences in 28- and 90-days mortality, volume infused in the
first 4 days, hemostatic changes, or incidence of acute kidney
injury. Furthermore, urinary biomarkers showed no signifi-
cant differences regarding tubular or glomerular involvement.
There was no information on whether burn patients were
included.
CHEST [5], another important multicenter study, analyzed
7000 patients, and burns were considered an exclusion
criterion. HES (130/0.4) was compared with 0.9% saline for
resuscitation in intensive care patients. In this study HES was
associated with a higher incidence of renal replacement
therapy as indicated by the attending doctor, although there
were no significant differences in the severity of acute kidney
injury estimated by the RIFLE score, and more patients were
classified in the risk and injury stage in the saline group. No
significant differences were found for 90-days mortality, ICU
stay, or hospital stay. Creatinine concentration and UO were
significantly higher in patients receiving saline, but in the HES
group creatinine values were around 100mmol/L and diuresis
1500mL/day; hence the differences would seem to have little
clinical relevance.
In CRISTAL [6], a multicenter study including 2857 pa-
tients, burn victims with >20% BSA involvement were
excluded. Resuscitation with colloids (HES, dextrans, gelat-
ins, and albumin) or crystalloids (0.9% saline, hypertonic
solutions, and Ringer’s lactate [RL]) was compared in
intensive care patients in hypovolemic shock. There were
no significant differences in mortality at 28 days, but the
survival rate was higher in colloid-treated patients at 90 days.
The colloid group remained more days without vasopressor
therapy and had a lower incidence of mechanical ventilation.
Of note, the study population was very heterogeneous and
there were differences in mortality between centers. This
study also provided separate data on mortality in HES-
treated patients. This group also showed no significant
differences with regard to mortality at 28 or 90days except in
the comparison of patients who received only one type of
fluid. In this analysis, 90 days mortality was significantly
lower in patients receiving HES than in those given isotonic
saline solution.
As to the VISEP [7] study, it is important to note that the
starch used was hypertonic pentastarch, a formula that
differs completely from the fourth-generation isotonic
starches currently used in Europe. Hence, as these are
different products, the results obtained should not be
extrapolated to other starches. VISEP was a randomized
multicenter study including 537 patients with sepsis who
underwent resuscitation with HES 200/0.5 (10%) or RL.
Mortality did not differ between the groups, but renal failure
and RRT rates were significantly higher in the HES group.
There was no mention of burn patients at any point in the
article. Furthermore, the authors reported protocol viola-
tions and stated that the HES dose administered was 2400mL
in 24h, an amount almost double the maximum dose used in
Europe.
Two studies specifically assessing HES use in burn patients
are available, both by the same author [9,10]. The first,
published in 2010 [9], included 30 patients and compared
resuscitation using mixed therapy (crystalloids+HES 200/0.5
[10%]) with RL-based therapy. Mortality and renal failure were
somewhat higher in the HES group, but the results were not
significant. The second study, published in 2013, was a
randomized, double-blind study with 48 patients comparing
resuscitation with RL or with mixed therapy (RL+HES 130/0.4
[6%]). In this case there were no differences in terms of
mortality, renal failure, or other associated morbidities
between the two groups [10].
Following the HES alert, various authors have voiced
concern about the methodology used in the studies upon
which it was based [11,12], and several new studies and
reviews on HES use in different types of patients have
emerged. More than 20 new related studies are registered
in Clinical Trials, and one of them, still to be published, is
in burn patients [13]. In addition, a long-term, cost-
effectiveness study was carried out in a CHEST cohort in
2016 that found no differences in mortality or any of the
other indicators evaluated at long term between the HES
and 0.9% saline groups [14]. For our part, we conducted a
retrospective study whose preliminary results were recent-
ly presented in the 2017 European Anaesthesiology Con-
gress. The study, performed in major burn patients, found
no significant differences in mortality at 28 or 90days
associated with administration of HES 130/0.4 versus other
fluids [15].
The results of the analysis of these studies are shown in
Table 1. It is surprising that only one study in 798 patients
actually found a higher mortality rate in patients receiving
HES 130/0.42 and only at 90 days, not at 28 days. Moreover,
the authors reported a greater RRT requirement without
specifying whether the indication was for renal failure.
Finally, major burn patients were excluded from this study
[3]. None of the available studies performed with HES 130/
0.4 found differences in mortality in burn patients or
critically ill patients.
As is well recognized, RRT use cannot be equated with
end-stage renal failure and even less so if the criteria for
starting RRT are not clearly established in the study protocol.
Various reasons apart from renal failure can prompt the
clinician to decide on RRT. We consider the lack of
information on what constituted severe renal failure in
these studies to be a limitation affecting the interpretation of
the results.
This analysis of the current evidence regarding HES use in
major burn patients leads us to conclude that despite the
European Medicines Agency recommendations set down four
years ago, to this day there is still no scientific evidence
supporting a contraindication for last-generation HES use in
patients with burn injuries. None of the related studies have
shown an increase in mortality or renal failure in major burn
patients treated with HES.
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